

Michael A Postow

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4008252/michael-a-postow-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

134
papers

32,314
citations

59
h-index

143
g-index

143
ext. papers

39,750
ext. citations

13.9
avg, IF

7.24
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 134 | Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.. <i>JAMA Oncology</i> , 2022 , | 13.4 | 3 |
| 133 | Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. 2022 , 10, | | 2 |
| 132 | Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series.. <i>Oncologist</i> , 2022 , 27, e350-e352 | 5.7 | |
| 131 | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. <i>Cell</i> , 2022 , 185, 563-575.e11 | 56.2 | 11 |
| 130 | The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.. <i>Journal of Translational Medicine</i> , 2022 , 20, 179 | 8.5 | |
| 129 | Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101570 | 2.2 | 2 |
| 128 | The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021 , 27, 1516-1525 | 12.9 | 2 |
| 127 | Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 2021 , 9, | | 2 |
| 126 | Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2021 , 22, 1692-1704 | 21.7 | 23 |
| 125 | Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.. <i>Frontiers in Immunology</i> , 2021 , 12, 810388 | 8.4 | 4 |
| 124 | Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab 2021 , 9, | | 1 |
| 123 | Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2021 , | 44.5 | 10 |
| 122 | Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 820-822 | 9.7 | 5 |
| 121 | Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. <i>Cancer</i> , 2021 , 127, 2062-2073 | 6.4 | 12 |
| 120 | Dermatologic infections in cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1528-1536 | 4.5 | 3 |
| 119 | Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021 , 23, 1961-1973 | 11.7 | 24 |
| 118 | Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021 , 27, 1432-1441 | 50.5 | 57 |

| | | | |
|-----|--|------|----|
| 117 | The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021 , 53, 11-15 | 36.3 | 38 |
| 116 | Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021 , 12, 729 | 17.4 | 44 |
| 115 | Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade 2021 , 9, | | 3 |
| 114 | LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021 , 13, | 17.5 | 14 |
| 113 | A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>OncotImmunology</i> , 2021 , 10, 1898105 | 7.2 | 2 |
| 112 | Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021 , 27, 2226-2235 | 12.9 | 6 |
| 111 | Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events.. <i>Clinical Cancer Research</i> , 2021 , | 12.9 | 3 |
| 110 | TNFBlockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?. <i>Clinical Cancer Research</i> , 2020 , 26, 2085-2086 | 12.9 | 3 |
| 109 | A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 3193-3201 | 12.9 | 14 |
| 108 | Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. <i>Oncologist</i> , 2020 , 25, 140-149 | 5.7 | 22 |
| 107 | Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1655-1663 | 2.2 | 72 |
| 106 | A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10003-10003 | 2.2 | 13 |
| 105 | Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1239-1253 | 4.5 | 30 |
| 104 | Intravitreal Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. <i>Ophthalmology</i> , 2020 , 127, 240-248 | 7.3 | 11 |
| 103 | High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. <i>Cancer</i> , 2020 , 126, 76-85 | 6.4 | 46 |
| 102 | Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. <i>Melanoma Research</i> , 2020 , 30, 71-75 | 3.3 | 12 |
| 101 | Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1180-1188 | 3.1 | 21 |
| 100 | Immune-Directed Molecular Imaging Biomarkers. <i>Seminars in Nuclear Medicine</i> , 2020 , 50, 584-603 | 5.4 | 2 |

| | | | |
|----|---|------|------|
| 99 | Imaging findings of immune checkpoint inhibitor associated pancreatitis. <i>European Journal of Radiology</i> , 2020 , 131, 109250 | 4.7 | 7 |
| 98 | Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020 , 70, 193-199 | 11.6 | 44 |
| 97 | First-in-Humans Imaging with Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 512-519 | 8.9 | 86 |
| 96 | Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3350-3358 | 2.2 | 23 |
| 95 | Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2746-2758 | 2.2 | 84 |
| 94 | Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019 , 25, 759-766 | 50.5 | 95 |
| 93 | Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389 | 21.7 | 88 |
| 92 | A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS9600-TPS9600 | 2.2 | 11 |
| 91 | Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. <i>Oncologist</i> , 2019 , 24, e196-e197 | 5.7 | 22 |
| 90 | Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases. <i>JAMA Dermatology</i> , 2019 , 155, 347-352 | 5.1 | 8 |
| 89 | The brim of uncertainty in adjuvant treatment of melanoma. <i>Lancet Oncology, The</i> , 2018 , 19, 436-437 | 21.7 | 3 |
| 88 | Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. <i>Cancer Medicine</i> , 2018 , 7, 690-697 | 4.8 | 56 |
| 87 | LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. <i>Cell</i> , 2018 , 172, 825-840.e18 | 56.2 | 181 |
| 86 | Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2018 , 378, 158-168 | 59.2 | 1834 |
| 85 | Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. <i>Clinical Cancer Research</i> , 2018 , 24, 730-736 | 12.9 | 8 |
| 84 | MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018 , 10, | 17.5 | 227 |
| 83 | Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 722-730 | 59.2 | 659 |
| 82 | Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018 , 33, 1017-1032.e7 | 24.3 | 81 |

| | | | |
|----|--|--------|-----|
| 81 | Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018 , 4, 98-101 | 13.4 | 98 |
| 80 | Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 391-398 | 2.2 | 118 |
| 79 | Reply to M. Horiguchi et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 721 | 2.2 | 1 |
| 78 | Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3925-3930 | 5.6 | 71 |
| 77 | Computed tomography-derived assessments of regional muscle volume: Validating their use as predictors of whole body muscle volume in cancer patients. <i>British Journal of Radiology</i> , 2018 , 91, 20180451 | 2.4 | 8 |
| 76 | A step forward for patients with NRAS-mutant melanoma. <i>Lancet Oncology, The</i> , 2017 , 18, 414-415 | 21.7 | 5 |
| 75 | Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017 , 73, 61-70 | 7.5 | 59 |
| 74 | Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017 , 18, 56-61 | 8.8 | 67 |
| 73 | T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017 , 545, 60-65 | 50.4 | 850 |
| 72 | Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017 , 25, 2155-2167 | 3.9 | 7 |
| 71 | Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. <i>Melanoma Research</i> , 2017 , 27, 57-64 | 3.3 | 27 |
| 70 | Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. <i>Cancer Treatment Reviews</i> , 2017 , 58, 70-76 | 14.4 | 173 |
| 69 | Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy 2017 , 5, 8 | | 86 |
| 68 | Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1989-1996 | 31.996 | 22 |
| 67 | Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017 , 109, | 9.7 | 41 |
| 66 | Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment 2017 , 5, 76 | | 78 |
| 65 | Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3807-3814 | 2.2 | 264 |
| 64 | OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017 , 2017, | 3.6 | 699 |

| | | | |
|----|--|------|------|
| 63 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356 | 59.2 | 2030 |
| 62 | Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?. <i>Lancet Oncology</i> , 2017 , 18, 1144-1145 | 21.7 | 1 |
| 61 | Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. <i>Ophthalmology</i> , 2017 , 124, 1788-1798 | 7.3 | 59 |
| 60 | Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017 , 82, 80-91 | 7.5 | 55 |
| 59 | Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 709-717 | 2.2 | 587 |
| 58 | Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. <i>Oncotarget</i> , 2017 , 8, 105000-105010 | 3.3 | 6 |
| 57 | The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016 , 122, 3354-3362 | 6.4 | 164 |
| 56 | Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 1558-1568 | 21.7 | 627 |
| 55 | Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016 , 21, 848-54 | 5.7 | 115 |
| 54 | Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 2908-18 | 12.9 | 372 |
| 53 | Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016 , 167, 231-50 | 3.5 | 33 |
| 52 | Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016 , 18, 21 | 6.3 | 32 |
| 51 | Primary Mucosal Melanomas of the Head and Neck 2016 , 641-656 | | |
| 50 | Proportions of blood-borne V α 1+ and V α 2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016 , 64, 116-26 | 7.5 | 36 |
| 49 | Reply to A. Indini et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1018-9 | 2.2 | |
| 48 | Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. <i>Experimental Dermatology</i> , 2016 , 25, 553-4 | 4 | 11 |
| 47 | Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. <i>Head and Neck</i> , 2016 , 38, 1310-7 | 4.2 | 46 |
| 46 | Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. <i>JAMA Oncology</i> , 2016 , 2, 1346-1353 | 13.4 | 493 |

| | | | |
|----|---|------|------|
| 45 | Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016 , 44, 1069-78 | 32.3 | 314 |
| 44 | Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016 , 22, 5487-5496 | 12.9 | 373 |
| 43 | Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016 , 4, 383-9 | 12.5 | 199 |
| 42 | Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016 , 22, 4848-4858 | 12.9 | 108 |
| 41 | The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1490-1493 | 11.6 | 156 |
| 40 | Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. <i>Oncologist</i> , 2016 , 21, 1230-1240 | 5.7 | 165 |
| 39 | Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. <i>New England Journal of Medicine</i> , 2015 , 372, 2006-17 | 59.2 | 2001 |
| 38 | On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015 , 7, 280sr1 | 17.5 | 113 |
| 37 | Safety of Infusing Ipilimumab Over 30 Minutes. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3454-8 | 2.2 | 19 |
| 36 | Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3826-33 | 2.2 | 234 |
| 35 | Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. <i>Nature</i> , 2015 , 526, 453-7 | 50.4 | 144 |
| 34 | Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3193-8 | 2.2 | 697 |
| 33 | Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015 , 2, 339-352 | 2.1 | 1 |
| 32 | Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. <i>British Journal of Haematology</i> , 2015 , 171, 84-90 | 4.5 | 11 |
| 31 | Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma 2015 , 3, 23 | | 134 |
| 30 | Liver resection and ablation for metastatic melanoma: A single center experience. <i>Journal of Surgical Oncology</i> , 2015 , 111, 962-8 | 2.8 | 16 |
| 29 | Managing immune checkpoint-blocking antibody side effects. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 76-83 | 7.1 | 271 |
| 28 | Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 368-75 | 4 | 268 |

| | | | |
|----|---|------|------|
| 27 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34 | 59.2 | 5047 |
| 26 | Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015 , 25, 208-24 | 24.7 | 126 |
| 25 | Immune checkpoint modulation: rational design of combination strategies. <i>Pharmacology & Therapeutics</i> , 2015 , 150, 23-32 | 13.9 | 62 |
| 24 | Immune modulation in cancer with antibodies. <i>Annual Review of Medicine</i> , 2014 , 65, 185-202 | 17.4 | 366 |
| 23 | Checkpoint blocking antibodies in cancer immunotherapy. <i>FEBS Letters</i> , 2014 , 588, 368-76 | 3.8 | 184 |
| 22 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , 2014 , 384, 1109-17 | 40 | 1340 |
| 21 | Opportunistic infections in patients treated with immunotherapy for cancer 2014 , 2, 19 | | 78 |
| 20 | Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 986-97 | 4 | 112 |
| 19 | Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. <i>Journal of Translational Medicine</i> , 2014 , 12, 08 | 8.5 | 17 |
| 18 | CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. <i>Frontiers in Oncology</i> , 2014 , 4, 385 | 5.3 | 135 |
| 17 | Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. <i>Cancer Immunology Research</i> , 2014 , 2, 812-21 | 12.5 | 97 |
| 16 | Genetic basis for clinical response to CTLA-4 blockade in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 2189-2199 | 59.2 | 2802 |
| 15 | Ipilimumab in patients with melanoma and autoimmune disease 2014 , 2, 35 | | 70 |
| 14 | Current options and future directions in the systemic treatment of metastatic melanoma. <i>Journal of Community and Supportive Oncology</i> , 2014 , 12, 20-6 | | 5 |
| 13 | Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. <i>Methods in Molecular Biology</i> , 2014 , 1102, 83-95 | 1.4 | 6 |
| 12 | Nivolumab plus ipilimumab in advanced melanoma. <i>New England Journal of Medicine</i> , 2013 , 369, 122-33 | 59.2 | 3118 |
| 11 | Checkpoint modulation in melanoma: an update on ipilimumab and future directions. <i>Current Oncology Reports</i> , 2013 , 15, 500-8 | 6.3 | 17 |
| 10 | Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. <i>Cancer Immunology Research</i> , 2013 , 1, 92-8 | 12.5 | 118 |

| | | | |
|---|---|------|------|
| 9 | Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. <i>Cancer</i> , 2013 , 119, 3687-95 | 6.4 | 143 |
| 8 | Ipilimumab for patients with advanced mucosal melanoma. <i>Oncologist</i> , 2013 , 18, 726-32 | 5.7 | 117 |
| 7 | The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?. <i>Clinical Cancer Research</i> , 2012 , 18, 1821-3 | 12.9 | 24 |
| 6 | Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. <i>Clinical Sarcoma Research</i> , 2012 , 2, 16 | 2.5 | 40 |
| 5 | Immunologic correlates of the abscopal effect in a patient with melanoma. <i>New England Journal of Medicine</i> , 2012 , 366, 925-31 | 59.2 | 1503 |
| 4 | Mucosal melanoma: pathogenesis, clinical behavior, and management. <i>Current Oncology Reports</i> , 2012 , 14, 441-8 | 6.3 | 93 |
| 3 | Chemotherapy in the Rwandan countryside: universal issues a world away. <i>Annals of Internal Medicine</i> , 2012 , 156, 60-1 | 8 | 0 |
| 2 | Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 153-9 | 2.2 | 23 |
| 1 | Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 372-8 | 2.2 | 24 |